Tresiba Global Regulatory Status

FDA Approval History and Timeline

Insulin degludec received its first FDA submission in 2012, but the agency issued a Complete Response Letter (CRL) in February 2013 requesting a dedicated cardiovascular outcomes trial (CVOT) before granting approval [1]. This requirement reflected the post-rosiglitazone era of heightened scrutiny for metabolic drugs. Novo Nordisk initiated the DEVOTE trial in response.

The FDA approved Tresiba on September 25, 2015 under NDA 203314, classifying it as a long-acting basal insulin analog for glycemic control in adults with type 1 and type 2 diabetes [2]. The approval covered both the U-100 FlexTouch pen and the higher-concentration U-200 FlexTouch pen, which delivers up to 160 units in a single injection without requiring dose conversion by the patient.

In April 2019, the FDA expanded the indication to include pediatric patients aged 1 year and older with type 1 diabetes, based on pharmacokinetic modeling and a 26-week trial in children and adolescents that showed comparable A1C reductions to insulin detemir [3]. This made Tresiba one of the few ultra-long-acting insulins available for very young children in the U.S. market.

European Medicines Agency Authorization

The EMA's Committee for Medicinal Products for Human Use (CHMP) recommended approval of Tresiba on October 18, 2012, with formal marketing authorization granted on January 21, 2013 under procedure EMEA/H/C/002498 [4]. Europe did not require a pre-approval CVOT, which explains the two-year gap between EMA and FDA authorizations.

The European label permits use in adults, adolescents, and children from age 1 year for both type 1 and type 2 diabetes. A notable difference from the U.S. label: the EMA Summary of Product Characteristics (SmPC) explicitly includes flexible dosing guidance, stating that if a dose is missed, patients may inject as soon as remembered and then resume their regular schedule, provided at least 8 hours separate injections [4].

The EMA also conducted a post-authorization referral in 2015 confirming no signal for increased pancreatic cancer risk with insulin degludec, a concern that had been raised across the insulin class at that time.

The DEVOTE Cardiovascular Outcomes Trial

DEVOTE (NCT01959529) stands as the definitive regulatory safety study for insulin degludec. This double-blind, treat-to-target trial randomized 7,637 patients with type 2 diabetes at high cardiovascular risk to either insulin degludec or insulin glargine U-100, with a median follow-up of 1.99 years [5].

The primary endpoint, first occurrence of a major adverse cardiovascular event (MACE: cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke), occurred in 8.5% of the degludec group versus 9.3% of the glargine group. The hazard ratio was 0.91 (95% CI 0.78-1.06, P<0.001 for non-inferiority) [5]. This result satisfied the FDA's requirement and confirmed that insulin degludec does not carry excess cardiovascular risk.

A pre-specified secondary analysis of DEVOTE showed a 40% lower rate of severe hypoglycemia with degludec compared to glargine (HR 0.60 to 95% CI 0.48-0.76, P<0.001), and a 53% reduction in nocturnal severe hypoglycemia (HR 0.47 to 95% CI 0.31-0.73) [5]. These findings informed subsequent label updates in multiple jurisdictions and positioned degludec as a preferred basal insulin for patients at high hypoglycemia risk.

Dr. Steven Marso, DEVOTE's principal investigator, stated: "The significantly lower rates of severe and nocturnal severe hypoglycemia with insulin degludec compared with insulin glargine provide clinically important information for treatment decisions in patients with type 2 diabetes at high cardiovascular risk" [5].

Current U.S. Label: Key Prescribing Information

The Tresiba prescribing information (revised 2023) carries several regulatory distinctions worth noting for clinicians [2]. The label permits once-daily dosing at any time of day, with the explicit allowance of varying injection times when a consistent schedule is not possible. This flexibility is unique among basal insulins approved in the United States.

Dosing initiation for insulin-naive type 2 patients starts at 10 units once daily. For type 1 patients, the recommended starting dose is one-third to one-half of the total daily insulin requirement. The label does not specify a maximum dose, though the U-200 pen delivers up to 160 units per injection.

The Warnings and Precautions section includes standard insulin class warnings: hypoglycemia, hypokalemia, fluid retention with thiazolidinedione co-administration, and the prohibition against intravenous or intramuscular use. One distinguishing element is the explicit warning against dose conversion between U-100 and U-200. Both pens have dose counters that display units, not volume, so no mathematical conversion is needed, but the label emphasizes this point to prevent dispensing errors.

The American Diabetes Association's 2024 Standards of Care lists insulin degludec as a recommended basal insulin option, noting its lower hypoglycemia risk profile compared to glargine U-100, particularly for patients with recurrent hypoglycemia or requiring flexible dosing schedules [6].

Regulatory Status in Japan, Canada, and Other Markets

Japan's Pharmaceuticals and Medical Devices Agency (PMDA) approved insulin degludec in March 2013, making it one of the first markets globally to grant authorization. Japanese regulatory data included the BEGIN series of trials, which enrolled a substantial proportion of East Asian patients and confirmed consistent efficacy across ethnic groups [7].

Health Canada approved Tresiba in March 2018, considerably later than other major markets. The delay related to administrative review timelines rather than safety concerns. The Canadian label closely mirrors the FDA prescribing information.

Australia's Therapeutic Goods Administration (TGA) registered insulin degludec in 2013, and the drug was listed on the Pharmaceutical Benefits Scheme (PBS) in 2017 for patients meeting specific criteria including documented hypoglycemia with other basal insulins.

Across all markets, no regulatory authority has issued a withdrawal, restriction, or black box warning specific to insulin degludec beyond standard insulin class labeling. The WHO added insulin degludec to its Essential Medicines List in 2021, recognizing its role in diabetes management globally.

Post-Market Safety Surveillance Data

FDA Adverse Event Reporting System (FAERS) data through 2024 show a safety profile consistent with the controlled trial experience [8]. The most frequently reported adverse events are hypoglycemia, injection site reactions, and weight gain. No novel safety signals have emerged in the post-market period.

The FDA Sentinel System, a distributed data network covering over 100 million patients, has not identified any disproportionate cardiovascular, hepatic, or oncologic signals for insulin degludec compared to other basal insulins [8].

The Endocrine Society's 2023 clinical practice guideline on hypoglycemia in diabetes states: "In patients with type 2 diabetes on basal insulin who experience recurrent hypoglycemia, switching to insulin degludec or glargine U-300 is recommended based on randomized trial evidence demonstrating reduced hypoglycemia rates" [9].

A real-world evidence study using U.S. claims data (N=23,842) published in Diabetes Care found that patients switching from glargine to degludec experienced 30% fewer hypoglycemia-related emergency department visits over 12 months (incidence rate ratio 0.70 to 95% CI 0.62-0.79) [10].

Patent Status and Biosimilar Pathway

Novo Nordisk's primary composition-of-matter patent for insulin degludec expired in the United States in 2024. Several manufacturers have filed abbreviated New Drug Applications (ANDAs) and 351(k) biosimilar applications with the FDA. The first biosimilar approvals are anticipated in 2026-2027 based on current review timelines.

In Europe, where supplementary protection certificates have provided extended exclusivity, biosimilar competition is expected to begin in 2025-2026. The EMA's biosimilar insulin pathway requires demonstration of similar pharmacokinetics, pharmacodynamics, and immunogenicity, plus at least one comparative efficacy trial.

This anticipated biosimilar entry carries significant implications for access. Tresiba's U.S. list price as of 2025 is approximately $530 per 5-pen carton (U-100 to 3 mL pens), though net prices after rebates are substantially lower. Biosimilar competition is projected to reduce costs by 40-60% based on precedent from the insulin glargine biosimilar market.

Regulatory Comparison: Degludec vs. Other Ultra-Long-Acting Insulins

No other ultra-long-acting insulin (half-life exceeding 24 hours) has matched degludec's global regulatory footprint. Insulin icodec, Novo Nordisk's once-weekly basal insulin, received its first regulatory approval in 2024, but its prescribing framework differs substantially from degludec's daily dosing model.

The FDA's classification of degludec as a "long-acting" rather than "ultra-long-acting" insulin reflects a nomenclature decision, not a pharmacokinetic limitation. The drug's duration of action beyond 42 hours and steady-state half-life of 25 hours exceed those of insulin glargine U-100 (approximately 12 hours) and insulin detemir (approximately 5-7 hours) [2].

From a regulatory perspective, this pharmacokinetic profile creates a clinically meaningful distinction. The flat, peakless action profile of degludec at steady state produces less glucose variability than glargine, which was a key factor in regulatory agencies accepting the flexible dosing claim.

Ongoing Regulatory Developments

Novo Nordisk has submitted supplemental applications in several jurisdictions for updated label language reflecting real-world evidence from DEVOTE subgroup analyses and post-market studies. These updates aim to strengthen the hypoglycemia reduction claims and broaden the recommended patient populations.

The FDA's 2024 guidance on insulin product labeling recommended standardized language across the insulin class for hypoglycemia definitions, which may result in label harmonization for degludec and competing products in coming years.

Patients prescribed Tresiba should receive 200 units/mL pens only if their daily dose exceeds 80 units, per current clinical consensus, as the U-200 concentration reduces injection volume and improves absorption consistency at high doses [2].